Tarsus Pharmaceuticals (TARS) Competitors

Elanco Animal Health (NYSE:ELAN) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Does the media refer more to ELAN or TARS?

In the previous week, Elanco Animal Health had 1 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 4 mentions for Elanco Animal Health and 3 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.59 beat Elanco Animal Health's score of 0.41 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tarsus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ELAN or TARS?

Elanco Animal Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Do analysts prefer ELAN or TARS?

Elanco Animal Health presently has a consensus target price of $15.17, indicating a potential upside of 10.14%. Tarsus Pharmaceuticals has a consensus target price of $66.67, indicating a potential upside of 65.84%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Tarsus Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tarsus Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Is ELAN or TARS more profitable?

Elanco Animal Health has a net margin of 8.43% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Elanco Animal Health's return on equity of 7.54% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	8.43%	7.54%	3.57%
Tarsus Pharmaceuticals	-44.91%	-39.72%	-25.74%

Do institutionals and insiders believe in ELAN or TARS?

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 0.9% of Elanco Animal Health shares are held by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has higher earnings & valuation, ELAN or TARS?

Elanco Animal Health has higher revenue and earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.44B	1.54	$338M	$0.74	18.61
Tarsus Pharmaceuticals	$182.95M	9.23	-$115.55M	-$2.73	-14.73

Summary

Elanco Animal Health beats Tarsus Pharmaceuticals on 10 of the 17 factors compared between the two stocks.